HomeAI · summaries
Storia in 2 fonti
Margin pressure, slower growth outlook may cap upside for Sun Pharma stock
Sun Pharma reported strong revenue and profit growth in the March quarter, but EBITDA margins faced pressure from increased investments and lower milestone income. The company anticipates range-bound margins and moderating revenue growth in FY27, driven by specialty launches and R&D spending. Domestic formulations remain robust, while US segment recovery is expected to be gradual.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Sun Pharma Q4 Results: Cons profit rises 26% YoY to Rs 2,714 crore; board approves Rs 5/share dividend
Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore…
- ·
thehindubusinessline.com
Sun Pharma Q4 net profit up 26% at ₹2,714 crore
Sun Pharma's Q4 net profit rises 26% to ₹2,714 crore, driven by robust formulation sales and strong overall revenue growth.
